Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.

Autor:	Harasymowycz P; Ophthalmology, University of Montreal, Montreal, Québec, Canada., Royer C; Pharmacoeconomics and Outcomes Research, PeriPharm Inc, Montreal, Québec, Canada., Cui AX; Market Access, Bausch Health Canada Inc, Laval, Quebec, Canada., Barbeau M; Market Access, Bausch Health Canada Inc, Laval, Quebec, Canada., Jobin-Gervais K; Market Access, Bausch Health Canada Inc, Laval, Quebec, Canada., Mathurin K; Pharmacoeconomics and Outcomes Research, PeriPharm Inc, Montreal, Québec, Canada.; Pharmacy, Université de Montréal, Montreal, Quebec, Canada., Lachaine J; Pharmacoeconomics and Outcomes Research, PeriPharm Inc, Montreal, Québec, Canada jean.lachaine@umontreal.ca.; Pharmacy, Université de Montréal, Montreal, Quebec, Canada., Beauchemin C; Pharmacoeconomics and Outcomes Research, PeriPharm Inc, Montreal, Québec, Canada.; Pharmacy, Université de Montréal, Montreal, Quebec, Canada.
Jazyk:	angličtina
Zdroj:	The British journal of ophthalmology [Br J Ophthalmol] 2022 May; Vol. 106 (5), pp. 640-647. Date of Electronic Publication: 2021 Jan 04.
DOI:	10.1136/bjophthalmol-2020-317262
Abstrakt:	Background/aims: To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP). Methods: A systematic literature review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%, latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated. Results: A total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (-3.45 (-4.77 to -2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed latanoprost (-0.70 (-1.83 to 0.43)) and tafluoprost (-0.41 (-1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(-1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (-0.17 (-1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%. Conclusion: LBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%. Competing Interests: Competing interests: PH has received consultant honoraria from Bausch Health, Canada. CR is an employee of PeriPharm Inc. AXC, MB and KJ-G are employees of Bausch Health, Canada. KM is an employee of PeriPharm and Université de Montréal. JL and CB have received research funds from Bausch Health, Canada to conduct this study. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu